IN2014DN05772A - - Google Patents

Info

Publication number
IN2014DN05772A
IN2014DN05772A IN5772DEN2014A IN2014DN05772A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A IN 5772DEN2014 A IN5772DEN2014 A IN 5772DEN2014A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A
Authority
IN
India
Prior art keywords
galectin
medicament
novel compounds
compounds
ligandsin
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf Nilsson
Hakon Leffler
Balaram Mukhopadhyay
Vishal Rajput
Original Assignee
Galecto Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech Ab filed Critical Galecto Biotech Ab
Publication of IN2014DN05772A publication Critical patent/IN2014DN05772A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN5772DEN2014 2012-01-25 2013-01-24 IN2014DN05772A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152413.6A EP2620443A1 (fr) 2012-01-25 2012-01-25 Nouveaux inhibiteurs de galectines au galactoside
PCT/EP2013/051339 WO2013110704A1 (fr) 2012-01-25 2013-01-24 Nouveaux inhibiteurs galactosides de galectines

Publications (1)

Publication Number Publication Date
IN2014DN05772A true IN2014DN05772A (fr) 2015-04-10

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5772DEN2014 IN2014DN05772A (fr) 2012-01-25 2013-01-24

Country Status (8)

Country Link
US (1) US9353141B2 (fr)
EP (2) EP2620443A1 (fr)
JP (1) JP6158840B2 (fr)
CN (1) CN104066743B (fr)
CA (1) CA2854986C (fr)
ES (1) ES2559857T3 (fr)
IN (1) IN2014DN05772A (fr)
WO (1) WO2013110704A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP5183844B2 (ja) 1999-11-03 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー 糖尿病の治療方法
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
CA2926480A1 (fr) * 2012-11-15 2014-05-22 Tufts University Methodes, compositions et kits de traitement, de modulation ou de prevention de l'angiogenese ou de la fibrose oculaire chez un sujet utilisant un inhibiteur de galectine
JP2016507503A (ja) 2012-12-20 2016-03-10 ヘンリー フォード ヘルス システム ガレクチン−３を阻害することによる拡張期心不全を治療する方法
JP6735680B2 (ja) * 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
WO2017152048A1 (fr) * 2016-03-04 2017-09-08 Galectin Sciences, Llc Composés de sélénogalactoside pour la prévention et le traitement de maladies associées à la galectine et leur utilisation
US10988502B2 (en) * 2016-07-12 2021-04-27 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
US10889610B2 (en) * 2016-07-12 2021-01-12 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
US11576924B2 (en) 2017-05-12 2023-02-14 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3102155A1 (fr) * 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugues
BR112021012482A2 (pt) 2018-12-27 2021-09-08 Glycomimetics, Inc. C-glicosídeos inibidores de galectina-3
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
ES2611206T3 (es) 2008-05-16 2017-05-05 Galecto Biotech Ab Derivados de di-(3-deoxi-3-1H-1,2,3-triazol-1-il)-beta-D-galacto-iranosil)sulfano como inhibidores de galectina-3
WO2010126435A1 (fr) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Nouveaux inhibiteurs galactosides de galectines
IN2015DN02573A (fr) 2012-10-31 2015-09-11 Galecto Biotech Ab

Also Published As

Publication number Publication date
CA2854986C (fr) 2019-09-17
EP2807176B1 (fr) 2015-12-30
CA2854986A1 (fr) 2013-08-01
JP2015504909A (ja) 2015-02-16
JP6158840B2 (ja) 2017-07-05
CN104066743B (zh) 2016-04-06
WO2013110704A1 (fr) 2013-08-01
US9353141B2 (en) 2016-05-31
EP2620443A1 (fr) 2013-07-31
EP2807176A1 (fr) 2014-12-03
US20140336146A1 (en) 2014-11-13
ES2559857T3 (es) 2016-02-16
CN104066743A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
IN2014DN05772A (fr)
AU2012214029A8 (en) Rorgammat inhibitors
MD20140002A2 (ro) Indazoli
MY160241A (en) 5-alkynyl-pyrimidines
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
PH12016500225A1 (en) Novel quinoline-substituted compound
NZ705135A (en) Heteroaryl compounds and methods of use thereof
EA024702B8 (ru) Новые иммуномодуляторные и противовоспалительные соединения
IN2014MN02459A (fr)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
IN2015DN01151A (fr)
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2013011132A (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
WO2012061754A3 (fr) Composés et procédés pour traiter des maladies auto-immunes
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
UA111628C2 (uk) Композиція для боротьби з хворобою рослини та її застосування
MX349548B (es) Compuestos de tienopirimidina.
MX2014002988A (es) Proceso y composicion para inhibir la polimerizacion de compuestos de ciclopentadieno.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.